United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2002_register executive 2010-09-23 article Part IV Rules and Regulations D09002ee1c8191f70 D09002ee1c8192088 United States Department of Justice originator org United States Government Agency or Subagency United States Drug Enforcement Administration originator org United States Government Agency or Subagency DEA is publishing a final rule regarding the registration and reregistration fees charged to controlled substances registrants. DEA is required to charge reasonable fees relating to the registration and control of the manufacture, distribution, and dispensing of controlled substances. To address this mandate, on March 22, 1993 DEA published a final rule in the Federal Register, establishing registration fees for controlled substances registrants (58 FR 15272). Following publication of the final rule, the American Medical Association (AMA) and others filed a complaint in the United States District Court for the District of Columbia objecting to the new fees. The district court issued its final order granting the government's motion for summary judgment and disposing of all claims. The AMA appealed. The United States Court of Appeals for the District of Columbia Circuit found DEA's rulemaking to be inadequate. The appeals court remanded, without vacating, the rule to DEA, requiring the agency to provide an opportunity for meaningful notice and comment on the fee-funded components of the Diversion Control Program. DEA responded to the remand requirement through a document published in the Federal Register on December 30, 1996 (61 FR 68624). This Final Rule supplements the December 30, 1996 Federal Register document and with that document, constitutes the final rule on the Drug Diversion Control Fee Account. 67 FR 51988 https://www.govinfo.gov/app/details/FR-2002-08-09/02-19667 02-19667 fr09au02-16 RIN 1117-AA34 4410-09-P DEA-140F https://www.govinfo.gov/app/details/FR-2002-08-09/02-19667 https://www.govinfo.gov/content/pkg/FR-2002-08-09/html/02-19667.htm https://www.govinfo.gov/content/pkg/FR-2002-08-09/pdf/02-19667.pdf 20 p. 51988 52007 67 FR 51988 Title 21 Part 1301 21 CFR Part 1301 RIN 1117-AA34 Registration and Reregistration Application Fees; Federal Register Vol. 67, Issue RULE 02-19667 IV DEPARTMENT OF JUSTICE Drug Enforcement Administration DEA-140F 4410-09-P 02-19667 Confirmation of final rule, remanded for further notice and comment, and response to comments.

DEA is publishing a final rule regarding the registration and reregistration fees charged to controlled substances registrants. DEA is required to charge reasonable fees relating to the registration and control of the manufacture, distribution, and dispensing of controlled substances. To address this mandate, on March 22, 1993 DEA published a final rule in the Federal Register, establishing registration fees for controlled substances registrants (58 FR 15272). Following publication of the final rule, the American Medical Association (AMA) and others filed a complaint in the United States District Court for the District of Columbia objecting to the new fees. The district court issued its final order granting the government's motion for summary judgment and disposing of all claims. The AMA appealed. The United States Court of Appeals for the District of Columbia Circuit found DEA's rulemaking to be inadequate. The appeals court remanded, without vacating, the rule to DEA, requiring the agency to provide an opportunity for meaningful notice and comment on the fee-funded components of the Diversion Control Program. DEA responded to the remand requirement through a document published in the Federal Register on December 30, 1996 (61 FR 68624). This Final Rule supplements the December 30, 1996 Federal Register document and with that document, constitutes the final rule on the Drug Diversion Control Fee Account.

(a) That DEA deposit each fiscal year's fee revenue in excess of $15 million into an account for "offsetting receipts" (i.e., the first $15 million collected must remain in the General Fund of the Treasury); (b) that revenue deposited into such account "remain available until expended"; (c) that the fees funding this account "be set at a level that ensures the recovery of the full costs of the various aspects" of the DCP; (d) that DEA "be refunded in accordance with estimates made in the budget request of the Attorney General"; and (e) that the Attorney General "prepare and submit annually to the Congress, statements of financial conditions of the account". 21 U.S.C. 886a. Patricia M. Good, Chief, Liaison and Policy Section, Office of Diversion Control, Drug Enforcement Administration, Washington, DC, 20537, Telephone (202) 307-7297. Controlled substances; manufacturers, distributors, and dispensers; registration: Diversion control program; registration and reregistration application fee schedule; adjustment, Vol. 67, no. 154 Office of the Federal Register, National Archives and Records Administration 2002-08-09 continuing daily deposited born digital 639 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2002-08-09 P0b002ee1809b4bfa 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr09au02 https://www.govinfo.gov/app/details/FR-2002-08-09 https://www.govinfo.gov/content/pkg/FR-2002-08-09/pdf/FR-2002-08-09.pdf https://www.govinfo.gov/content/pkg/FR-2002-08-09/xml/FR-2002-08-09.xml fdlp 51751 52381 DGPO 2010-09-23 2024-06-07 FR-2002-08-09 machine generated eng FR FR-2002-08-09 67 154